Liliana Soroceanu, MD PhD
About Liliana Soroceanu, MD PhD
Liliana Soroceanu, MD PhD, serves as the Translational Medicine Biomarker Lead and Senior Principal Scientist at ORIC Pharmaceuticals Inc. in South San Francisco, California, where she focuses on designing and executing biomarker strategies for clinical trials.
Work at ORIC Pharmaceuticals
Liliana Soroceanu currently serves as the Translational Medicine - Biomarker Lead and Senior Principal Scientist at ORIC Pharmaceuticals Inc. She has held this position for 10 months, starting in 2023, in South San Francisco, California. In her role, she focuses on the design and execution of translational and biomarker strategies specifically for first-in-human clinical trials.
Previous Experience in Translational Medicine
Before joining ORIC Pharmaceuticals, Liliana Soroceanu worked at Kinnate Biopharma Inc. as the Director of Translational Medicine for 9 months in 2023. She also spent 8 years at CPMC Research Institute, where she served as a Senior Scientist and Principal Investigator for the Cancer Avatar Program from 2015 to 2023. Her earlier experience includes a role as a Scientist at CPMC Research Institute from 2007 to 2015 and as a Postdoctoral Research Fellow at Genentech from 2002 to 2007.
Education and Expertise
Liliana Soroceanu holds a Doctor of Medicine (MD) degree from Grigore T. Popa University of Medicine and Pharmacy Iași. She also earned a Doctor of Philosophy (PhD) in Neurobiology from the University of Alabama at Birmingham. Her expertise includes liquid biopsy analysis for monitoring disease progression and treatment response, as well as advanced techniques like nanostring multiplex spatial proteomic analysis to study tumor microenvironments.
Research Techniques and Applications
In her research, Liliana Soroceanu employs various advanced methodologies, including RNA-seq and DNA mutational analysis for precision oncology applications. She utilizes patient-derived primary cell culture systems and high-throughput drug screens to enhance her research efforts, particularly in the context of immunotherapy-resistant tumors.